12/20
07:36 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) was downgraded by analysts at Evercore ISI from an "outperform" rating to an "inline" rating. They now have a $6.00 price target on the stock, down previously from $15.00.
Medium
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) was downgraded by analysts at Evercore ISI from an "outperform" rating to an "inline" rating. They now have a $6.00 price target on the stock, down previously from $15.00.
12/19
07:42 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $6.00 price target on the stock, down previously from $12.00.
Neutral
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $6.00 price target on the stock, down previously from $12.00.
12/10
06:02 am
caba
Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
Medium
Report
Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
11/30
07:10 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Medium
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
11/26
08:06 am
caba
Cabaletta Bio to Participate in Upcoming Investor Conferences in December [Yahoo! Finance]
Medium
Report
Cabaletta Bio to Participate in Upcoming Investor Conferences in December [Yahoo! Finance]
11/26
08:00 am
caba
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
Medium
Report
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
11/18
05:41 pm
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "outperform" rating re-affirmed by analysts at William Blair.
Medium
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "outperform" rating re-affirmed by analysts at William Blair.
11/18
07:12 am
caba
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 [Yahoo! Finance]
High
Report
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 [Yahoo! Finance]
11/18
07:00 am
caba
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
High
Report
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
11/15
03:26 pm
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $12.00. They now have an "overweight" rating on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $12.00. They now have an "overweight" rating on the stock.
11/15
08:03 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
High
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
11/14
07:09 am
caba
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/14
07:00 am
caba
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
11/6
08:00 am
caba
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Medium
Report
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
10/10
07:32 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $10.00 price target on the stock.
Medium
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $10.00 price target on the stock.
9/25
04:38 pm
caba
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 [Yahoo! Finance]
Low
Report
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 [Yahoo! Finance]
9/25
04:30 pm
caba
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
Low
Report
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024